BOCA RATON, Fla., May 12 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that its stockholders elected the Company's eight Board of Director nominees at its Annual Meeting of Stockholders held today in Boca Raton, Florida. Approximately 74 percent of the Company's outstanding shares were voted either in person or by proxy at the meeting, with each director receiving the support of at least 87 percent of those shares voted. The directors have been elected to serve a term expiring at the Company's 2007 annual meeting of stockholders.
In addition, the appointment of Ernst & Young LLP was ratified as the Company's independent registered public accounting firm for the fiscal year ending December 30, 2006.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and market products that fight serious medical conditions. The company has three products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM) (allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on developing products that address unmet medical needs and offer commercial opportunities in our core business areas: Gram-positive bacterial infections, hepatitis and transplant, kidney disease (nephrology) and nicotine addiction. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php . The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our website: http://www.nabi.com .
Nabi BiopharmaceuticalsCONTACT: Thomas E. Rathjen, Vice President, Investor Relations, NabiBiopharmaceuticals, +1-561-989-5800